Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the innovation, development, and commercialization of life-transforming therapeutic products for treating patients with severe and ultra-rare disorders in the United States, Europe, Latin America, Japan, and the Asia Pacific. It focuses on developing products for the treatment of diseases in the areas of hematology, nephrology, neurology, metabolic disorders, oncology, and ophthalmology. The company offers Soliris(eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), an ultra-rare and life-threatening genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult. In addition, the company conducts various Phase II clinical trail programs on Soliris for its usage for the treatment of cold agglutinin disease; hemolytic uremic syndrome; dense deposit disease; presensitized renal transplant; ABO incompatible renal transplant; myasthenia gravis; neuromyelitis optica; and dry age-related macular degeneration. It is developing Asfotase alfa, a Phase II clinical trail program for the treatment of metabolic disorders, including hypophosphatasia; and Phase I clinical trail products comprising TT30 for hematology and Samalizumab for the treatment of oncology diseases, such as chronic lymphocytic leukemia and multiple myeloma. Further, the company conducts preclinical trails on cPMP for metabolic disorders. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.